Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?

Feldmann M, Maini RN.

J Immunol. 2010 Jul 15;185(2):791-4. doi: 10.4049/jimmunol.1090051.

2.

Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.

Feldmann M, Maini RN.

Joint Bone Spine. 2002 Jan;69(1):12-8. Review.

PMID:
11858351
3.

Infliximab treatment of rheumatoid arthritis.

Maini SR.

Rheum Dis Clin North Am. 2004 May;30(2):329-47, vii. Review.

PMID:
15172044
4.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

PMID:
11961174
6.

Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.

[No authors listed]

Prescrire Int. 2010 Feb;19(105):30-4. Review.

PMID:
20455343
7.

[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].

Tijhuis GJ, van de Putte LB, Breedveld FC.

Ned Tijdschr Geneeskd. 2001 Sep 29;145(39):1880-5. Review. Dutch.

PMID:
11605312
8.

[Anti-TNF-alpha therapy as a new option in treatment of rheumatoid arthritis?].

Leeb BF, Sautner J.

Wien Med Wochenschr. 1999;149(19-20):554-7. Review. German.

PMID:
10637966
9.

[Infliximab for therapy of rheumatoid arthritis].

Amano K.

Nihon Rinsho. 2005 Jan;63 Suppl 1:517-20. Review. Japanese. No abstract available.

PMID:
15799410
10.

Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?

Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P, Williams R, Woody J, Maini RN.

Novartis Found Symp. 2004;256:53-69; discussion 69-73, 106-11, 266-9. Review.

PMID:
15027483
11.

Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.

Richard-Miceli C, Dougados M.

BioDrugs. 2001;15(4):251-9. Review.

PMID:
11437690
12.

Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?

O'Dell JR.

N Engl J Med. 1999 Jan 28;340(4):310-2. No abstract available.

PMID:
9920958
13.

Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.

[No authors listed]

Prescrire Int. 2004 Oct;13(73):171-5.

PMID:
15499697
14.

Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?

Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V.

J Rheumatol. 2006 Feb;33(2):433; author reply 433-4. No abstract available.

PMID:
16465676
15.

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

Keating GM, Perry CM.

BioDrugs. 2002;16(2):111-48. Review.

PMID:
11985485
17.

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.

Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E.

Ann Rheum Dis. 2011 Feb;70(2):266-71. doi: 10.1136/ard.2010.132134. Epub 2010 Nov 19. Review. Erratum in: Ann Rheum Dis. 2011 Mar;70(3):560.

PMID:
21097801
18.

TNF inhibitors in the treatment of arthritis.

Lorenz HM.

Curr Opin Investig Drugs. 2000 Oct;1(2):188-93. Review.

PMID:
11249572
19.

TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action.

Elliott MJ, Feldmann M, Maini RN.

Int J Immunopharmacol. 1995 Feb;17(2):141-5. Review.

PMID:
7544768
20.

Anti-tumor necrosis factor therapies.

Taylor PC.

Curr Opin Rheumatol. 2001 May;13(3):164-9. Review.

PMID:
11333343

Supplemental Content

Support Center